Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

被引：2
|
作者：
Daemen, Anneleen
Pankov, Aleksandr
Barkund, Shravani
Zhou, Haiying
Duff, Maureen
Johnson, Ann
Xu, Rongda
Multani, Pratik S.
Maneval, Edna Chow
Friedman, Lori
机构：
[1] 240 E Grand Ave, San Francisco, CA USA
[2] ORIC Pharmaceut, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors
    Attard, G
    Kitzen, JJ
    de Bono, J
    Verweij, J
    Pronk, L
    Zhi, J
    Blagden, SP
    Reade, SE
    Zugmaier, G
    de Jonge, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 232S - 232S
  • [32] Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis
    Cock, Terrie-Anne
    Bishop, Anthony
    Kruger, Nicole
    McCormack, Sarah
    Harris, Marion
    Ananda, Sumitra
    Lipton, Lara
    Nagrial, Adnan
    Pavlakis, Nick
    Joubert, Warren
    Donato, Laura
    Lickliter, Jason
    Burns, Christopher
    CANCER RESEARCH, 2024, 84 (07)
  • [33] Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
    Westin, Shannon N.
    Fu, Siqing
    Tsimberidou, Apostolia
    Piha-Paul, Sarina
    Akhmedzhanov, Fechukwu
    Yilmaz, Bulent
    McQuinn, Lacey
    Brink, Amanda L.
    Gong, Jing
    Leung, Cheuk Hong
    Lin, Heather
    Hong, David S.
    Pant, Shubham
    Carter, Brett
    Jazaeri, Amir
    Gershenson, David
    Sood, Anil K.
    Coleman, Robert L.
    Shah, Jatin
    Meric-Bernstam, Funda
    Naing, Aung
    GYNECOLOGIC ONCOLOGY, 2023, 168 : 76 - 82
  • [34] Results of study PX-171-007 a phase 1b/2 study of carfilzomib, a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors
    Gordon, M.
    Infante, J.
    Papadopoulos, K. P.
    Lee, P.
    Sausville, E.
    Mendelson, D.
    Wong, A. F.
    Vallone, M.
    Rosen, P. J.
    Burris, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 123
  • [35] Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Johnson, M.
    Benson, B.
    Wei, R.
    Brachmann, R.
    Galsky, M. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.
    Ben Tran
    Carvajal, Richard D.
    Belle, Aurelien Mara
    Patel, Sandip P.
    LoRusso, Patricia
    Rasmussen, Erik
    Juan, Gloria
    Upreti, Vijay V.
    Ngarmchamnanrith, Gataree
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Mifepristone (MIFE), a glucocorticoid receptor (GR) antagonist, in combination with eribulin (E) in advanced solid tumors: A phase 1 study with dose expansion in patients (pts) with triple-negative breast cancer (TNBC)
    Nanda, Rita
    Wilks, Sharon
    Modiano, Manuel R.
    Spira, Alexander I.
    Becerra, Carlos
    Walling, Jackie
    Dat Nguyen
    Baker, Gabrielle
    Conzen, Suzanne D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.
    Harb, Wael A.
    Sessa, Cristiana
    Hirte, Hal W.
    Kaye, Stanley B.
    Banerjee, Susana N.
    Christinat, Alexandra
    Simantov, Ronit
    Singh, Margaret
    Sternberg, David W.
    Light, Rebecca
    Poondru, Srinivasu
    Naumann, R. Wendel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
    Thein, Kyaw Z.
    Fu, Siqing
    Janku, Filip
    Tsimberidou, Apostolia M.
    Piha-Paul, Sarina A.
    Karp, Daniel D.
    Shah, Jatin
    Milton, Denai R.
    Gong, Jing
    Sulovic, Selma
    McQuinn, Lacey
    Stephen, Bettzy A.
    Colen, Rivka R.
    Carter, Brett W.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (01) : 10 - 12
  • [40] A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Chien, Amy Jo
    Cockerill, Alyson
    Fancourt, Craig
    Schmidt, Emmett
    Moasser, Mark M.
    Rugo, Hope S.
    Melisko, Michelle E.
    Ko, Andrew H.
    Kelley, R. Katie
    Korn, W. Michael
    Esserman, Laura J.
    van't Veer, Laura
    Yau, Christina
    Wolf, Denise M.
    Munster, Pamela N.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 521 - 530
12345